Trials / Completed
CompletedNCT04895293
RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration
Evaluation of RBM-007 in Subjects With Treatment naïve Exudative Age-related Macular Degeneration (AMD)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Maturi, Raj K., M.D., P.C. · Individual
- Sex
- All
- Age
- 50 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-center, open label, 4-month study, designed to evaluate the safety and treatment efficacy of RBM-007 in patients with intraretinal or subretinal edema due to previously untreated neovascular AMD. Up to 5 subjects will be randomized to receive study medication. Study treatment will be administered by intravitreal injections.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RBM-007 Injectable Solution | Sterile solution |
Timeline
- Start date
- 2021-06-15
- Primary completion
- 2022-02-08
- Completion
- 2022-03-04
- First posted
- 2021-05-20
- Last updated
- 2023-04-12
- Results posted
- 2023-04-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04895293. Inclusion in this directory is not an endorsement.